You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Sciences Announces Notification of ANDA Filing for Truvada
Gilead Sciences to Present at Three Upcoming Investor Conferences
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B
Gilead Sciences to Present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Gilead Signs Agreement with EFI to Acquire Building and Associated Land Bordering Gilead's Foster City Campus
Gilead Sciences Announces Third Quarter 2008 Financial Results
Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008
Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis
Seigo Izumo, MD Joins Gilead as Senior Vice President, Cardiovascular Therapeutics
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Richard J. Whitley, MD Joins Gilead Sciences' Board of Directors
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV
Gilead Sciences Announces Second Quarter 2008 Financial Results
Gilead Sciences to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008
Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Gilead Sciences to Present at the 29th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11
U.S. Patent Office Confirms Second of Four Viread(R) Patents
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Gilead Sciences' Chairman and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan
U.S. Patent Office Confirms First of Four Viread(R) Patents
Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms
Gilead Sciences to Present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Gilead Sciences to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13
Gilead Appoints John C. Martin as Chairman of Board of Directors; Names John F. Milligan President
Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program
European Commission Approves Viread(R) for Chronic Hepatitis B
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B
Robin L. Washington to Join Gilead as Senior Vice President and Chief Financial Officer
Gilead Sciences Announces First Quarter 2008 Financial Results
Gilead Sciences to Release First Quarter 2008 Financial Results on Wednesday, April 16, 2008
European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepatitis B
Gilead Sciences Submits Marketing Authorisation Application for Aztreonam Lysine 75 mg Powder for Nebuliser Solution, a Potential New Treatment for Cystic Fibrosis, to European Medicines Agency
Gilead Appoints Dr. John J. Toole as Senior Vice President, Corporate Development
Gilead Announces $500 Million Accelerated Share Repurchase
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5
Gilead Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
Gilead Announces Departure of Caroline Dorsa
Gilead Sciences to Release Fourth Quarter and Year End 2007 Financial Results on Wednesday, January 23, 2008
Gilead Sciences to Present at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7
2012 Interactive Annual Report